Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

In this case report, a 3-year-old male with IFAP syndrome showed moderate improvement in skin symptoms and corneal erosions but no change in alopecia or photophobia after 6 months of acitretin therapy.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

This article reviews the clinicopathologic features of short anagen syndrome in a child and suggests diagnostic methods like clinical examination and scalp hair growth rate measurement, without reporting new clinical results.

This study reported that over 70% of adults with primary cicatricial alopecia experienced impaired quality of life, primarily influenced by trichodynia and anxiety.

This study found that patients with severe alopecia areata are willing to accept increased risks of serious infection, cancer, and blood clots when opting for a higher dose of ritlecitinib, valuing the potential for greater hair regrowth efficacy compared to a lower dose.

This study found that hirsutism in females with facial hair causes significant psychosocial impact and financial burden, with laser therapy being notably costly compared to other treatments.

This letter raises concerns about the limited attention given to scalp reduction in hair restoration fields, with no new research data reported.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This article highlights disparities in the prevalence of alopecia areata among people with skin of color and suggests this information could help dermatologic providers address challenges in treating this population.

Patients found AI helpful for alopecia diagnosis but want it to support, not replace, doctors.

This study from the Danish Skin Cohort found that patients with alopecia areata, followed by those with hidradenitis suppurativa, were willing to spend the most daily time on treatment, reflecting possible unmet needs, and that this willingness correlated with disease severity across different dermatological conditions.

This study found that greater root surface area due to root hairs contributed to better growth and zinc uptake of wild-type barley compared to its root-hairless mutant in zinc-deficient soil.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This study reported that ritlecitinib effectively improved hair regrowth in JAK inhibitor-naïve adolescent patients with severe alopecia areata, achieving significant reductions in SALT scores within 24 weeks, but was less effective for patients who had previously been treated with baricitinib.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

This study suggests that clinically apparent fragile hair in children is rarely linked to trichothiodystrophy, and the tiger-tail pattern is not wholly specific to this diagnosis.

This case report describes a patient with pseudopelade affecting both the scalp and beard area, highlighting the unusual presentation of a rare hair disorder.

This case report discusses how trichomegaly, an adverse effect of the cancer therapy drug erlotinib, might serve as a marker of positive tumor response and potentially aid in treating madarosis.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study observed that most patients with traction alopecia showed improved or stabilized hair loss with therapeutic counseling and adjunctive treatments, but follow-up was often inconsistent, highlighting the need for better awareness and management.